We are a pre-clinical drug development company focused on novel therapies to target cancer, with specific focus on kidney cancer.
In 2024, kidney cancer will afflict more than 81,000 people in the United States. The estimated 5-year survival rate for patients with metastatic kidney cancer is only 15%.
At Kuda, our mission is to create a new paradigm for the treatment of cancer.
We have developed a revolutionary small molecule with a dual mechanism of action of blocking the tumor driver, hypoxia-inducible factor (HIF)-2α and inducing cell death through excessive iron accumulation (ferroptosis).
The combination of ferroptosis induction + HIF-2α inhibition is a game-changing cancer treatment strategy with compelling anti-tumor activity in animal models.
In 2018, Kuda Therapeutics was awarded a $300,000 SBIR Phase 1 grant from the National Cancer Institute to develop its novel anti-cancer therapeutics.
In 2020, Kuda Therapeutics received a $560,000 Idea Award from the Department of Defense to advance its ferroptosis inducer technology.
In 2022, Kuda Therapeutics was awarded a $2,050,000 SBIR Phase II grant from the National Cancer Institute to advance this technology towards FDA Investigational New Drug (IND) filing for human proof-of-concept studies.
In 2024, Kuda Therapeutics was awarded a $420,000 Award from the Department Defense to investigate the utility of this revolutionary approach for the treatment of ovarian cancer.